Please login to the form below

Not currently logged in
Email:
Password:

Pharma urged to tackle non-compliance

The pharma industry must act to combat patient non-compliance, which averages at 50 per cent for long-term conditions, such as HIV and arthritis, according to a Capgemini report

The pharma industry must act to combat patient non-compliance, which averages at 50 per cent for long-term conditions, such as HIV and arthritis, according to a Capgemini report.

The report estimates that patient non-adherence to prescribed medicine courses is responsible for 194,500 deaths per year in the EU and 131,400 deaths per year in the US. Nonadherence results in annual costs of close to €125bn in the EU and $300bn in the US.

Jean-Marc Neimetz, global leader of the life sciences practice Capgemini Consulting, said: "The pharmaceutical industry needs to address patient adherence in a more strategic and integrated part of its activities, which will be good for the patients and for the industry overall."

They need to design and deploy programmes targeted to the very specific patient situations and leverage both traditional and digital approaches to do so, added Thomas Forissier, a principal of the life sciences practice at Capgemini Consulting.

The report said that almost all chronic conditions face high rates of non-adherence and those with no visible symptoms, such as depression, have the lowest adherence rates. The problem even extends to oral formulation chemotherapy drugs, where there is less expectation to counter patient adherence issues due to the seriousness of the condition. As much as 40 per cent of cancer patients are non-adherent in this case.

2nd June 2011

Share

Subscribe to our email news alerts

PMHub

Add my company
CHASE

We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....

Latest intelligence

Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....